ArticleArchives of osteoporosis2026
Medication-related osteonecrosis of the jaw in osteoporotic patients receiving antiresorptive therapy: prevalence and associated risk factors.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is an uncommon complication of antiresorptive therapy in osteoporosis. In this real-world cohort, longer treatment duration and tooth extraction were associated with MRONJ. These findings may improve risk assessment and support preventive dental management in high-risk patients.
objectiveMedication-related osteonecrosis of the jaw (MRONJ) is an uncommon but clinically important complication of antiresorptive therapy in osteoporosis. This study investigated the prevalence of MRONJ and factors associated with its development in osteoporotic patients receiving antiresorptive treatment.
methodsThis retrospective cohort study included patients with osteoporosis treated with antiresorptive agents between January 2020 and December 2025. Of 2153 screened records, 1131 met the inclusion criteria. Demographic, clinical, treatment-related, and oral-dental characteristics were collected. MRONJ was diagnosed and staged according to the 2022 American Association of Oral and Maxillofacial Surgeons (AAOMS) criteria. Factors associated with MRONJ were evaluated using univariate and multivariate logistic regression analyses.
resultsMRONJ was diagnosed in 26 of 1131 patients (2.3%). Patients with MRONJ had a significantly longer cumulative duration of antiresorptive therapy than those without MRONJ. Multivariable logistic regression analysis demonstrated that a longer cumulative duration of antiresorptive therapy (OR 1.03, 95% CI 1.01-1.06; p = 0.010) and a history of tooth extraction (OR 9.74, 95% CI 2.48-38.26; p = 0.001) were independently associated with MRONJ. Medication switching, drug holidays, diabetes mellitus, corticosteroid use, and immunosuppressive therapy were not independently associated with MRONJ. Among patients with MRONJ, 69.2% had stage 1 disease and 30.8% had stage 2 disease.
conclusionLonger antiresorptive treatment duration and tooth extraction were the main factors associated with MRONJ development. Careful dental assessment and multidisciplinary planning of invasive dental procedures may help reduce MRONJ risk in high-risk patients.
Indexed as
Identifiers
42645626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.